Among all cancer immunotherapy strategies, antibodies targeting the PD-1/PD-L1 interaction have been the most intensively evaluated in clinical trials and are currently approved for a wide range of malignancies including melanoma, non-small cell lung cancer, Hodgkin ́s lymphoma, head and neck squamous cell carcinoma or solid tumors presenting microsatellite instability (MSI) [3, 4]. This evidence concerns the gene CD274 and melanoma.